Scottish Biotech Aims To Cure Common Cold

UK News

Scottish biotech aims to cure common cold

Scottish biotech company ScotBio has announced that it has seen “promising initial results” from its attempts to extract a cure for the common cold from algae.

The Livingston-based company is assessing how waste molecules from Spirulina, an alga often consumed as a superfood, could be used as a cure for the common cold, COVID-19 and various other viruses.

This research comes in collaboration with the University of Edinburgh, Robert Gordon University and the Industrial Biotechnology Innovation Centre (IBioIC). The researchers are aiming to utilise the antiviral properties of the alga’s waste molecules.

Spirulina is currently used in the production of various other products including dietary supplements and food colourants. Separating the molecules of this substance into different chemical groups allows researchers to identify which molecules have more efficient antiviral properties to treat viruses such as COVID-19, the common cold or influenza.

Joe Palmer, ScotBio’s development manager, commented: “Working with the project consortium has enabled us to fractionate Spirulina into distinct chemical groups and then screen the extracts in a safe environment. Through that, we have identified compounds that could be particularly effective against a broad range of viruses from what was previously seen as waste. We can now work on recovering and purifying these molecules as high-value ingredients.”

“The next step for us is to better understand the market opportunities for these molecules and to fully resolve the relationship between molecule chemistry and their antiviral mechanisms,” Palmer continued. “Our aim is for this project to be a catalyst that will unlock a large and untapped market, helping in the fight against common viruses and future pandemics.”

UKHSA opens new vaccine research centre in Wiltshire to prepare for future pandemics

Ministers have opened a new vaccine research centre at the UKHSA Porton Down campus in Wiltshire, intended to prepare for 'disease x', the next possible pandemic pathogen.

Bristol Myers Squibb’s Sotyktu recommended to treat adult patients with psoriasis on the NHS

Bristol Myers Squibb has announced that NICE has recommended Sotyktu (deucravacitinib) for use on the NHS in England as a new treatment option for adult patients with moderate-to-severe plaque psoriasis.

Report finds NHS may miss out on new drugs due to rising costs

Figures from a team at the University of York, the London School of Economics and Political Science (LSE), and the London School of Hygiene and Tropical Medicine (LSHTM) have revealed that the total cost of prescription medicines to NHS England reached a new high of £17.2bn in 2021-22, and that since 2018, NHS spending on branded medicines have been increasing by over 5% annually.

Trade union Unite calls for GSK staff walkouts over pay increase disputes

UK-based trade union Unite were pushing for staff walkouts at several GSK manufacturing sites due to disputes regarding pay increases, however to date there have been no updates as to whether GSK have extended another offer.

Pharmacists in England given wider prescribing powers to relieve GP pressure

NHS England has announced that pharmacists in England will be given wider prescribing powers to relieve pressure put on GPs.

UKHSA opens new vaccine research centre in Wiltshire to prepare for future pandemics

Bristol Myers Squibb’s Sotyktu recommended to treat adult patients with psoriasis on the NHS

Report finds NHS may miss out on new drugs due to rising costs

Trade union Unite calls for GSK staff walkouts over pay increase disputes

Pharmacists in England given wider prescribing powers to relieve GP pressure

Pharmafocus

Categories

Social Footprints